十五烷-8-醇 | 1653-35-6

• 物质功能分类: 化学试剂 - 有机试剂 - 脂肪醇
• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 中文名称: 十五烷-8-醇
• 英文名称: pentadecan-8-ol
• 英文别名: 8-pentadecanol；Pentadecanol-(8)；pentadecane-8-ol
• CAS: 1653-35-6
• 化学式: C₁₅H₃₂O
• 分子量: 228.418
• InChiKey: AXCJQGZCVXCVAG-UHFFFAOYSA-N

物化性质

• 熔点：
  53.5-54.3 °C(Solv: ethyl acetate (141-78-6))
• 沸点：
  300.24°C (estimate)
• 密度：
  0.8221 (estimate)

计算性质

• 辛醇/水分配系数(LogP)：
  6.4
• 重原子数：
  16
• 可旋转键数：
  12
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 储存条件：
  室温

SDS

---

SECTION 1: Identification of the substance/mixture and of the company/undertaking
Product identifiers
Product name : 8-PENTADECANOL
REACH No. : A registration number is not available for this substance as the substance
or its uses are exempted from registration, the annual tonnage does not
require a registration or the registration is envisaged for a later
registration deadline.
CAS-No. : 1653-35-6
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances

---

SECTION 2: Hazards identification
Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008
Chronic aquatic toxicity (Category 4), H413
For the full text of the H-Statements mentioned in this Section, see Section 16.
This substance is not classified as dangerous according to Directive 67/548/EEC.
Label elements
Labelling according Regulation (EC) No 1272/2008
Pictogram none
Signal word none
Hazard statement(s)
H413 May cause long lasting harmful effects to aquatic life.
Precautionary statement(s) none
Supplemental Hazard none
Statements
Other hazards - none

---

SECTION 3: Composition/information on ingredients
Substances
Formula : C15H32O
Molecular Weight : 228,42 g/mol
CAS-No. : 1653-35-6
No components need to be disclosed according to the applicable regulations.
For the full text of the H-Statements and R-Phrases mentioned in this Section, see Section 16

---

SECTION 4: First aid measures
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Consult a physician.
In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in
section 11
Indication of any immediate medical attention and special treatment needed
no data available

---

SECTION 5: Firefighting measures
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Carbon oxides
Advice for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
no data available

---

SECTION 6: Accidental release measures
Personal precautions, protective equipment and emergency procedures
Avoid dust formation. Avoid breathing vapours, mist or gas. Ensure adequate ventilation.
For personal protection see section 8.
Environmental precautions
Prevent further leakage or spillage if safe to do so. Do not let product enter drains. Discharge into the
environment must be avoided.
Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

---

SECTION 7: Handling and storage
Precautions for safe handling
Provide appropriate exhaust ventilation at places where dust is formed.
For precautions see section 2.2.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Specific end use(s)
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated

---

SECTION 8: Exposure controls/personal protection
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and
at the end of workday.
Personal protective equipment
Eye/face protection
Use equipment for eye protection tested and approved under appropriate government standards
such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
Choose body protection in relation to its type, to the concentration and amount of dangerous
substances, and to the specific work-place., The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
Respiratory protection is not required. Where protection from nuisance levels of dusts are desired,
use type N95 (US) or type P1 (EN 143) dust masks. Use respirators and components tested and
approved under appropriate government standards such as NIOSH (US) or CEN (EU).
Control of environmental exposure
Prevent further leakage or spillage if safe to do so. Do not let product enter drains. Discharge into
the environment must be avoided.

---

SECTION 9: Physical and chemical properties
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour no data available
c) Odour Threshold no data available
d) pH no data available
e) Melting point/freezing no data available
point
f) Initial boiling point and no data available
boiling range
g) Flash point no data available
h) Evapouration rate no data available
i) Flammability (solid, gas) no data available
j) Upper/lower no data available
flammability or
explosive limits
k) Vapour pressure no data available
l) Vapour density no data available
m) Relative density no data available
n) Water solubility no data available
o) Partition coefficient: n- log Pow: 6,507
octanol/water
p) Auto-ignition no data available
temperature
q) Decomposition no data available
temperature
r) Viscosity no data available
s) Explosive properties no data available
t) Oxidizing properties no data available
Other safety information
no data available

---

SECTION 10: Stability and reactivity
Reactivity
no data available
Chemical stability
Stable under recommended storage conditions.
Possibility of hazardous reactions
no data available
Conditions to avoid
no data available
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products
In the event of fire: see section 5

---

SECTION 11: Toxicological information
Information on toxicological effects
Acute toxicity
no data available
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitisation
no data available
Germ cell mutagenicity
no data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
no data available
Specific target organ toxicity - single exposure
no data available
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Additional Information
RTECS: Not available
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.

---

SECTION 12: Ecological information
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
PBT/vPvB assessment not available as chemical safety assessment not required/not conducted
Other adverse effects
no data available

---

SECTION 13: Disposal considerations
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Dissolve or mix the material
with a combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.

---

SECTION 14: Transport information
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
no data available

---

---

SECTION 15 - REGULATORY INFORMATION
N/A

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  十五烷-8-醇 在 硫酸 、 铂 作用下， 生成 正十五烷
  参考文献：
  名称：

  Tuot; Guyard, Bulletin de la Societe Chimique de France, 1947, p. 1087,1092

  摘要：

  DOI：
• 作为产物：
  描述：

  8-十五烷酮 在 二异丁基氢化铝 作用下， 生成 十五烷-8-醇
  参考文献：
  名称：

  Bi（OTf）（3）催化的醇类与酸酐的强力实用酰化。

  摘要：

  与其他酰化方法相比，评估了Bi（OTf）（3）催化的酸酐与酸酐的酰化反应。Bi（OTf）（3）/酸酐操作规程如此强大，以至于空间需求量高的或叔醇都可以被平滑地酰化。反应性较低的酰化试剂，例如苯甲酸酯和新戊酸酐，也可以通过这种催化活化。在这些情况下，为了克服将酰化产物与剩余的酰化试剂分离的困难，开发了一种新技术：未反应的酸酐的甲醇化成易于分离的甲酯实现了所需酰化产物的非常容易的分离。Bi（OTf）（3）/酸酐方案适用于具有各种功能的多种醇。酸不稳定的THP或TBS保护的醇，糠醇，香叶醇和碱不稳定的醇也可以被酰化。在室温下甚至进行官能化叔醇的酰化。

  DOI：

  10.1021/jo0107453

文献信息

• IONIZABLE CATIONIC LIPID FOR RNA DELIVERY
  申请人：Arcturus Therapeutics, Inc.

  公开号：US20180169268A1

  公开（公告）日：2018-06-21

  What is described is a compound of formula I consisting of a compound in which R 1 is a branched chain alkyl consisting of 10 to 31 carbons; R 2 is a linear alkyl, alkenyl, or alkynyl consisting of 2 to 20 carbons; L 1 and L 2 are the same or different, each a linear alkylene of 1 to 20 carbons or a linear alkenylene of 2 to 20 carbons; X 1 is S or O; R 3 is a linear or branched alkylene consisting of 1 to 6 carbons; and R 4 and R 5 are the same or different, each a hydrogen or a linear or branched alkyl consisting of 1 to 6 carbons; or a pharmaceutically acceptable salt thereof.

  描述的是一种化合物，其化学式为I，包括以下成分： R1为由10至31个碳组成的支链烷基化合物； R2为由2至20个碳组成的直链烷基、烯基或炔基； L1和L2相同或不同，每个为由1至20个碳组成的直链烷基或由2至20个碳组成的直链烯基； X1为S或O； R3为由1至6个碳组成的直链或支链烷基； R4和R5相同或不同，每个为氢或由1至6个碳组成的直链或支链烷基；或其药用可接受盐。
• 苯并菲-柔性桥-苝二酰亚胺二元化合物及其 制备方法与应用
  申请人：江苏和成新材料有限公司

  公开号：CN106146495B

  公开（公告）日：2018-06-12

  本发明公开了一种苯并菲‑柔性桥‑苝二酰亚胺二元化合物及其制备方法与该化合物作为有机太阳能电池活性层的应用。与现有技术相比，本发明的苯并菲‑柔性桥‑苝二酰亚胺二元化合物，具有易于调节液晶相转变温度及温度区间的优点，使得该化合物具有光学、电光学和电子学目的的用途，特别是作为有机太阳能电池活性层的用途。
• Ni-Catalyzed Formal Cross-Electrophile Coupling of Alcohols with Aryl Halides
  作者：Quan Lin、Guobin Ma、Hegui Gong

  DOI：10.1021/acscatal.1c04239

  日期：2021.11.19

  and TBAB as the mild bromination reagents enables rapid transformation of a wide range of alcohols to their bromide counterparts within one to 5 min in CH3CN and DMF, which is compatible with the Ni-catalyzed cross-electrophile coupling conditions in the presence of a chemical reductant. The present method is suitable for arylation of a myriad of structurally complex alcohols with no need for prepreparation

  未活化醇的直接偶联仍然是当前合成化学中的一个挑战。我们在此展示了一种建立在醇与芳基卤化物的原位卤化/还原偶联以形成 Csp 2 -Csp 3键的策略。2-氯-3-乙基苯并[ d ]恶唑-3-鎓盐 (CEBO) 和 TBAB 作为温和溴化试剂的组合能够在 CH 3 中在一到 5 分钟内将范围广泛的醇快速转化为其溴化物对应物CN 和 DMF，在化学还原剂存在下与 Ni 催化的交叉亲电偶联条件相容。本方法适用于无数结构复杂的醇的芳基化，而无需制备卤代烷。更重要的是，温和且动力学快速的溴化过程在对称二醇的溴化/芳基化和多元醇中较少的空间位阻羟基中显示出良好的选择性，从而为二醇和多元醇的选择性官能化提供了希望，而无需费力的保护/脱保护操作。这项工作的实用性在许多碳水化合物、药物化合物和天然醇的芳基化中也很明显。
• [EN] COMPOUNDS USEFUL IN HIV THERAPY<br/>[FR] COMPOSÉS UTILES DANS LA THÉRAPIE DU VIH
  申请人：VIIV HEALTHCARE CO

  公开号：WO2021194828A1

  公开（公告）日：2021-09-30

  The invention relates to compounds of Formula (I), salts thereof, pharmaceutical compositions thereof, as well as methods of treating or preventing HIV in subjects.

  这项发明涉及公式（I）的化合物，其盐，药物组合物，以及治疗或预防HIV的方法。
• [EN] NOVEL SULFATED OLIGOSACCHARIDE DERIVATIVES<br/>[FR] NOUVEAUX DÉRIVÉS D'OLIGOSACCHARIDES SULFATÉS
  申请人：PROGEN PHARMACEUTICALS LTD

  公开号：WO2009049370A1

  公开（公告）日：2009-04-23

  The invention relates to novel compounds that have utility as inhibitors of heparan sulfate-binding proteins; compositions comprising the compounds, and use of the compounds and compositions thereof for the antiangiogenic, antimetastatic, anti-inflammatory, antimicrobial, anticoagulant and/or antithrombotic treatment of a mammalian subject.

  这项发明涉及具有作为肝素硫酸结合蛋白抑制剂的效用的新化合物；包含这些化合物的组合物；以及利用这些化合物和组合物对哺乳动物主体进行抗血管生成、抗转移、抗炎、抗微生物、抗凝血和/或抗血栓治疗的用途。